New tool may help prioritize high-risk infants for RSV immunization

On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious RSV LRTI, according to new research.

Related Keywords

Tennessee ,United States ,Vanderbilt University ,Netherlands ,Brittneym Snyder ,Tebeb Gebretsadik ,Tinav Hartert ,Niek Achten ,Centers For Disease Control Prevention ,Vanderbilt University Medical Center ,Department Of Biostatistics ,Division Of Allergy ,Erasmus University Medical Center ,Tennessee Medicaid Program ,Critical Care Medicine ,Vanderbilt University Medical ,Disease Control ,Principal Investigator Tina ,